Le Lézard
Classified in: Health
Subjects: TRI, FDA

Mezzion Pharma announces positive results from the Fontan Udenafil Exercise Longitudinal (FUEL) Trial, in adolescents with single ventricle heart disease who have undergone the Fontan procedure


SEOUL, Korea, July 30, 2019 /PRNewswire/ -- Mezzion Pharma Co. Ltd. today announced that top line data from the Phase 3 FUEL trial, which was designed to evaluate the safety and efficacy of udenafil for the treatment of certain adolescents with congenital single ventricle heart disease (SVHD), had positive results for key parameters. Although Mezzion is restricted in providing specific data results at the present time due to contractual obligation, the Company is looking forward to publication of the full results in a peer reviewed journal and the presentation of the clinical trial data at a major scientific meeting later this year.

The FUEL Trial is a study in 400 male and female adolescents with a single functional ventricle who had previously undergone Fontan surgical palliation. Study participants were drawn from a total of 30 Pediatric Heart Network http://www.pediatricheartnetwork.org/ (PHN) and auxiliary sites throughout the U.S., Canada, and Korea. The PHN is funded by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health.

In view of these results from the FUEL trial and the safety data collected about the drug candidate over other clinical studies, Mezzion Pharma intends to submit a New Drug Application to the U.S. Food and Drug Administration to seek approval for the use of udenafil to treat adolescents with SVHD who have undergone Fontan palliation.

In addition to this FUEL trial, Mezzion continues forward in its clinical efforts with the FALD study, also conducted under the auspices of the PHN, which is measuring the ability of udenafil to impact the effects of Fontan Associated Liver Disease.  

Mezzion Pharma Co. Ltd.

Mezzion Pharma is a publicly-listed biotech company in Korea focusing on the development of new drugs.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to FDA review and approval, product development and acceptance, manufacturing, competition, and/or other factors, which are outside the control of the Company.

Contact:

Mr. YT Song
Tel: +82 2 560 8011
Email: ytsong@mezzion.co.kr

SOURCE Mezzion Pharma Co. Ltd.


These press releases may also interest you

at 16:43
Dallas-based MedCore Partners recently added two members to its Senior Living team amidst the continued growth of its seniors housing platform. Anthony Fulco joined MedCore in August as the Seniors Housing Director of Acquisitions. Mr. Fulco brings...

at 16:35
Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on...

at 16:32
The world-class surgeons at Eyesthetica have been featured in Pasadena Magazine, honored among the top health practitioners of 2019. As the largest oculofacial surgery practice dedicated to eyelid and facial surgery in the Los Angeles area,...

at 16:30
Eli Lilly and Company will conduct a webcast on Wednesday, October 2, 2019 to discuss the company's presentations at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain. Remarks will focus primarily on data being...

at 16:30
The "The Arab Pharmacovigilance Guidelines" conference has been added to ResearchAndMarkets.com's offering On 1 July 2015, the Common Arab Guidelines on good vigilance practices became effective. The Guidelines represented fundamental changes to...

at 16:15
Align Technology, Inc. today announced a global distribution agreement for the award-winning iTero Element family of intraoral scanners with Zimmer Biomet Dental, a division of Zimmer Biomet and a global dental industry leader and provider of...



News published on 30 july 2019 at 19:42 and distributed by: